Regeneron Pharmaceuticals has lost the bankruptcy auction for 23andMe to former CEO Anne Wojcicki, whose nonprofit TTAM Research Institute submitted a $305 million bid exceeding Regeneron's $256 million offer. The transaction, pending court approval, ensures that 23andMe's genetic testing platform and research assets will be controlled by Wojcicki, who has committed to maintaining the company’s privacy policies amid user concerns. The deal concludes a tumultuous period for 23andMe, which filed for Chapter 11 in March 2025 after significant financial losses.